Clinical Trial

A Trial to Learn How Safe AZD9750 is and How Well it Works in People With Metastatic Prostate Cancer When Given With or Without Other Anticancer Drugs

Study acronym: ANDROMEDA
Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
ANDROMEDA is a first-in-human, Phase I/II, open-label, multicenter study of AZD9750 in participants with metastatic prostate cancer. The trial evaluates safety, tolerability, pharmacokinetics/pharmacodynamics, and preliminary efficacy of AZD9750 as monotherapy and in combination with saruparib.
Protocol Amendment History 2 changes
critical Recruitment opened 2026-05-02
notable Trial sites expanded: 9 -> 18 locations 2026-05-02
Trial Details
NCT Number NCT07336446
Lead Sponsor AstraZeneca
Conditions Prostate Cancer
Enrollment 300 participants
Start Date 2026-01-27
Primary Completion 2029-01-26 (estimated)
Study Completion 2029-01-26 (estimated)
Updated on ClinicalTrials.gov 2026-08-10